Jardiance Black / African Ancestry Dose Adjustments

Does Empagliflozin Require a Different Dose for Black or African Ancestry Patients?

No dose adjustment is required based on race or African ancestry alone. The FDA-approved labeling for Jardiance specifies the same 10 mg once-daily starting dose for all adults with type 2 diabetes, heart failure, or chronic kidney disease, without stratification by race or ethnicity. Pharmacokinetic studies have not identified clinically meaningful differences in empagliflozin absorption, distribution, metabolism, or elimination attributable to African ancestry.

What the Pharmacokinetic Data Actually Show

Empagliflozin is primarily metabolized via glucuronidation by UGT1A3, UGT1A8, UGT1A9, and UGT2B7, not by CYP450 enzymes. This metabolic pathway is less susceptible to the high-impact pharmacogenomic variants that affect CYP2C19 or CYP2D6 substrates, where ancestry-linked allele frequencies vary substantially. PharmGKB does not currently list any African ancestry-specific actionable pharmacogenomic variants for empagliflozin, though research in this area is ongoing.

Renal clearance accounts for a minor fraction of total empagliflozin elimination, and population pharmacokinetic modeling has shown that body weight and renal function explain most inter-individual variability in exposure, not race. Because Black adults in the United States have a higher prevalence of CKD at any given age, eGFR-based dose thresholds (detailed below) are disproportionately relevant in clinical practice for this population.

Standard Dosing Protocol

• Glycemic indication (type 2 diabetes): Start at 10 mg once daily in the morning, with or without food. Uptitrate to 25 mg once daily if additional A1c lowering is needed and eGFR ≥45 mL/min/1.73 m².
• Heart failure indication (HFrEF or HFpEF): 10 mg once daily. No uptitration studied or approved for this indication.
• CKD indication: 10 mg once daily. Can be initiated when eGFR ≥20 mL/min/1.73 m² and continued even if eGFR subsequently falls below this threshold, per FDA prescribing information.

Cardiovascular Efficacy in Black and African Ancestry Subgroups

The EMPA-REG OUTCOME trial (N=7,020) published in the New England England of Medicine in 2015 remains the foundational cardiovascular outcomes trial for empagliflozin. Black or African ancestry patients constituted approximately 4.9% of the trial population (roughly 362 participants). In the overall trial, empagliflozin reduced the primary MACE endpoint (cardiovascular death, non-fatal MI, or non-fatal stroke) by 14% relative to placebo (HR 0.86, 95% CI 0.74-0.99, P=0.04) [1].

Subgroup-Level Findings

Prespecified and exploratory subgroup analyses in EMPA-REG OUTCOME showed that the cardiovascular mortality benefit was directionally consistent across racial groups, though the Black subgroup was underpowered to generate a statistically independent conclusion. The 95% confidence intervals for this subgroup crossed the null, which is expected given a subgroup of roughly 362 participants. Absence of statistical significance in a small subgroup is not the same as evidence of no effect.

The cardiovascular death reduction (38% relative risk reduction in the overall trial) was driven primarily by a reduction in heart failure hospitalization and sudden cardiac death, two outcomes that are disproportionately prevalent in Black adults. Approximately 1 in 3 Black adults in the United States has cardiovascular disease, per American Heart Association data [2], making the mechanism of benefit (volume offloading, natriuresis, and cardiac energetics) potentially as or more relevant in this population.

Heart Failure Hospitalizations

The EMPEROR-Reduced trial (N=3,730) and EMPEROR-Preserved trial (N=5,988) both included Black patients as a minority subgroup. The heart failure hospitalization reduction of 25% (HR 0.75, 95% CI 0.65-0.86) in EMPEROR-Reduced was directionally consistent across prespecified demographic subgroups, though race-stratified data were not separately published for the Black subgroup at sufficient granularity for independent meta-analysis.

Renal Outcomes and CKD Risk in Black Adults

Black adults in the United States develop end-stage kidney disease at approximately 3.4 times the rate of white adults, according to CDC surveillance data [3]. Diabetic kidney disease and hypertension-driven nephrosclerosis are the two leading contributors. Empagliflozin now carries an FDA approval specifically for CKD (regardless of diabetes status), making it directly applicable to a population with disproportionate renal disease burden.

EMPA-KIDNEY Trial Results

The EMPA-KIDNEY trial (N=6,609, published in NEJM 2023) enrolled a broader CKD population than prior trials, including patients without diabetes. Empagliflozin reduced the composite kidney disease progression or cardiovascular death endpoint by 28% (HR 0.72, 95% CI 0.64-0.82, P<0.001) [4]. Black patients comprised approximately 10% of the EMPA-KIDNEY population, a higher representation than in EMPA-REG OUTCOME, and the benefit was directionally consistent in this subgroup.

eGFR Monitoring Schedule for Black Adults

Standard eGFR monitoring applies to all patients, but clinicians treating Black patients should be aware of the CKiD U25 study findings and ongoing debate about race-correction in eGFR calculation. The NKF-ASN Task Force recommends using race-free CKD-EPI 2021 equations [5]. Using the race-free equation can reclassify some Black patients to a higher CKD stage, which affects the eGFR thresholds relevant for empagliflozin dosing.

Practical implication: a Black patient whose eGFR was previously reported as 48 mL/min/1.73 m² using the race-adjusted equation might now have an eGFR of 42 mL/min/1.73 m² under CKD-EPI 2021, which changes the uptitration eligibility threshold for the glycemic indication (requires eGFR ≥45). Clinicians should confirm which eGFR equation their laboratory uses before making dosing decisions.

Hypertension, ACE Inhibitor Response, and Empagliflozin

Black adults have a higher prevalence of hypertension (approximately 56% in Black men and 57% in Black women, per CDC [6]) and tend to have blunted antihypertensive responses to ACE inhibitors and ARBs as monotherapy, likely due to lower baseline renin activity. This has historically shaped prescribing patterns toward calcium channel blockers and thiazide diuretics in this population, per JNC 8 and the American College of Cardiology/American Heart Association 2017 hypertension guidelines.

Why SGLT2 Inhibitors Are Different

Empagliflozin lowers blood pressure through an osmotic diuresis and natriuresis mechanism, not through the renin-angiotensin-aldosterone system. This mechanism is independent of the renin status that attenuates ACE inhibitor response. A pooled analysis of EMPA-REG OUTCOME and phase III trials showed empagliflozin reduced systolic blood pressure by approximately 3.0-4.2 mmHg and diastolic by 1.5-2.0 mmHg versus placebo, without orthostatic hypotension at meaningful rates. These blood pressure effects are not expected to be attenuated by low-renin status.

Combination with Renin-Angiotensin System Blockers

The 2022 ADA Standards of Care [7] recommend that adults with type 2 diabetes and hypertension receive an ACE inhibitor or ARB for renoprotection, particularly when urinary albumin-to-creatinine ratio exceeds 30 mg/g. Adding empagliflozin to an existing ACE inhibitor or ARB regimen in a Black patient with diabetic kidney disease represents combination nephroprotection targeting two complementary pathways: RAAS blockade and SGLT2-mediated glomerular hemodynamic effects. No dose adjustment of empagliflozin is needed when combined with ACE inhibitors or ARBs.

G6PD Deficiency: A Population-Specific Safety Consideration

G6PD deficiency affects an estimated 10-15% of men of African ancestry, compared to roughly 1-2% of men of European ancestry. This X-linked enzymatic deficiency affects red blood cell stability under oxidative stress. Empagliflozin itself is not a known oxidative stressor and is not contraindicated in G6PD deficiency. However, certain co-medications commonly prescribed alongside empagliflozin (including some sulfonamides and trimethoprim-sulfamethoxazole, which may be used to treat urinary tract infections that are more common with SGLT2 inhibitors) can precipitate hemolytic anemia in G6PD-deficient patients.

The table below outlines a practical screening and management framework for G6PD-related risk in Black patients starting empagliflozin.

| Clinical Step | Action | Rationale | |---|---|---| | Pre-prescription screen | Ask about prior hemolytic episodes or jaundice with antibiotics | Identifies likely G6PD deficiency without formal testing | | Formal G6PD testing | Consider in men with suggestive history or family history | Guides antibiotic selection for future UTIs | | UTI management | Prefer nitrofurantoin or fosfomycin over TMP-SMX in G6PD-deficient patients | Reduces hemolysis risk | | Genital mycotic infection treatment | Topical azoles preferred; systemic fluconazole is G6PD-safe | Standard management, no empagliflozin interaction | | Patient counseling | Inform patient of increased UTI and genital yeast infection risk with SGLT2 inhibition | Supports adherence and early reporting |

Pharmacogenomics: What Current Evidence Shows

Empagliflozin's UGT-based metabolism means the pharmacogenomic field differs from that of drugs metabolized by CYP2C19 (like clopidogrel) or CYP2D6 (like codeine), where African ancestry-linked allele variants have well-documented clinical consequences. UGT1A9 is the principal glucuronidating enzyme for empagliflozin, and polymorphisms in UGT1A9 have been studied in the context of other UGT substrates.

UGT1A9 Variants and Exposure

The UGT1A9*3 variant (rs72551330) reduces glucuronidation activity and has been associated with higher plasma exposure of UGT1A9 substrates. Its frequency in African ancestry populations is low (approximately 0.5-1%), comparable to European ancestry populations. No actionable clinical guidance for empagliflozin dose modification based on UGT1A9 genotype currently exists in the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling [8], and empagliflozin does not appear in that table.

SLC5A2 Gene Variation

The SGLT2 transporter itself is encoded by SLC5A2. Rare loss-of-function variants in SLC5A2 cause familial renal glucosuria and are distributed across ancestries without strong African-specific enrichment. Common SLC5A2 variants have not been shown to meaningfully alter empagliflozin response in published pharmacogenomic studies. A 2019 pharmacogenomics review in Clinical Pharmacokinetics [9] noted that SGLT2 inhibitor pharmacokinetics are more strongly influenced by renal function than by genetic variation in SLC5A2.

Practical Pharmacogenomic Takeaway

No clinical pharmacogenomic testing panel is recommended before prescribing empagliflozin in Black or African ancestry patients. The standard eGFR-based dosing adjustment framework applies uniformly. Clinicians should focus on eGFR trending, albuminuria measurement, and cardiovascular risk stratification rather than awaiting pharmacogenomic panel results.

Blood Pressure and Volume Management in Clinical Practice

Black adults with type 2 diabetes frequently present with volume-expanded, salt-sensitive hypertension, a phenotype that may respond particularly well to the osmotic and natriuretic effects of SGLT2 inhibition. The 2023 ACC/AHA Guideline on Chronic Coronary Disease [10] and the 2022 ADA Standards of Care [7] both recommend SGLT2 inhibitors in patients with type 2 diabetes and established cardiovascular disease, regardless of baseline A1c.

Starting Empagliflozin in a Patient Already on a Diuretic

Black patients with heart failure or resistant hypertension are often already prescribed loop diuretics (furosemide) or thiazide-type diuretics (chlorthalidone). Adding empagliflozin provides additive natriuresis. Clinicians should assess volume status at the first follow-up visit (typically 2-4 weeks after initiation) and consider reducing the loop diuretic dose by 20-40% if symptomatic hypotension, dizziness, or excessive thirst develops. This is a clinical judgment call without a published dose-reduction algorithm.

A1c Reduction Expectations

In patients of African ancestry, empagliflozin's glycemic efficacy has not been studied in a dedicated ethnicity-stratified RCT. The overall phase III program showed A1c reductions of approximately 0.6-0.8% from a baseline mean of approximately 8.0% at the 10 mg dose and approximately 0.7-0.9% at the 25 mg dose. These figures should be interpreted alongside the known higher prevalence of HbA1c assay interference with certain hemoglobin variants (notably HbS and HbC, which are more prevalent in African ancestry populations). Patients with known hemoglobinopathies should have A1c results interpreted cautiously, and fructosamine or continuous glucose monitoring may serve as complementary glycemic markers.

Practical Prescribing Checklist for Black and African Ancestry Patients

Before writing the prescription, a structured pre-prescription review improves safety outcomes in this population. The points below are not race-specific contraindications. They reflect a disproportionate clinical burden in Black adults that makes each item higher-yield to check.

1. Confirm eGFR using CKD-EPI 2021 (race-free) and verify the laboratory equation used.
2. Check urinary albumin-to-creatinine ratio. If UACR >300 mg/g, co-prescribe ACE inhibitor or ARB per ADA guidelines.
3. Ask about sickle cell disease or sickle trait. While not a contraindication, volume depletion from SGLT2 inhibition may theoretically precipitate sickling events, and clinical vigilance is warranted.
4. Ask about recurrent UTIs or prior genital infections before prescribing, since SGLT2 inhibitors increase glycosuria and mycotic infection risk.
5. Ask about prior hemolytic episodes to informally screen for G6PD deficiency.
6. Review current diuretic regimen and plan for possible dose reduction.
7. Confirm that blood pressure is not below 90/60 mmHg before initiation given the additional BP-lowering effect.

Initiation, Monitoring, and Follow-Up Timeline

| Timepoint | Action | |---|---| | Baseline | eGFR (CKD-EPI 2021), UACR, A1c or fructosamine, electrolytes, BP | | 2-4 weeks | Volume status assessment, BP check, symptom review | | 3 months | A1c, eGFR, UACR, review for genital or urinary infections | | 6 months | Consider uptitration to 25 mg if A1c above target and eGFR ≥45 | | Annually | Full metabolic panel, UACR, cardiovascular risk re-stratification |

A dip in eGFR of 10-15% within the first 4 weeks of starting empagliflozin is expected and does not warrant discontinuation. Per the 2022 KDIGO CKD guideline [11], an acute eGFR decline of up to 30% from baseline that stabilizes over 2-4 weeks is acceptable and reflects the intended hemodynamic effect on glomerular filtration pressure.